This approach addresses the limitations of traditional antiseptics by reducing pathogenic activity without triggering dysbiosis, potentially lowering long-term gum disease recurrence and related systemic health risks.

Extensive development, including biochemical and structural studies and GLP-compliant testing, supported safety and efficacy, using methods like scanning electron microscopy and chemical analysis to assess interactions with teeth and gums.

The formulation includes traditional abrasives and fluoride to prevent tooth decay and was tested under Good Laboratory Practice standards to verify safety and effectiveness.

The active compound guanidinoethylbenzylamino imidazopyridine acetate works by blocking growth of harmful bacteria rather than killing them, allowing healthy bacteria to reinstate balance.

The effort culminated in the creation of PerioTrap Pharmaceuticals GmbH in 2018 and the launch of a toothpaste designed to prevent periodontitis while retaining standard toothpaste benefits.

By preventing gingivitis progression and potentially reducing risks of systemic conditions linked to gum disease, the approach aims to safeguard broader health through a balanced oral microbiome.

A German research team has developed PerioTrap Microbiome Toothpaste that selectively inhibits harmful oral bacteria causing gum disease while preserving beneficial microbes to maintain the mouth’s healthy microbiome.

Beyond toothpaste, the PerioTrap line includes a post-cleaning gel that blocks harmful bacteria and supports a balanced microbiome, with plans for a mouthwash and other products; veterinary applications are also being considered due to similar gum disease mechanisms in animals.

The toothpaste is designed to allow beneficial bacteria to occupy niches, rather than killing all bacteria, promoting a balanced oral ecosystem under the brand PerioTrap Microbiome Toothpaste.

The researchers emphasize maintaining microbial balance over outright eradication, signaling a shift toward microbiome-friendly dental care.

PerioTrap originated as a spin-off from the Fraunhofer Institute for Cell Therapy and Immunology (IZI), illustrating an academic-to-commercial development path.

The strategy contrasts with alcohol- or chlorhexidine-based products that can disrupt the entire oral microbiome by killing both good and bad bacteria.